CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon
Publication
, Journal Article
Venook, A; Niedzwiecki, D; Lenz, HJ; Innocenti, F; Mahoney, MR; O'Neil, B; Shaw, J; Polite, B; Hochster, H; Atkins, J; Goldberg, R; Mayer, R ...
Published in: Annals of Oncology
June 1, 2014
Duke Scholars
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
June 1, 2014
Volume
25
Start / End Page
ii112
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Venook, A., Niedzwiecki, D., Lenz, H. J., Innocenti, F., Mahoney, M. R., O’Neil, B., … Blanke, C. (2014). CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon. Annals of Oncology, 25, ii112. https://doi.org/10.1093/annonc/mdu193.19
Venook, A., D. Niedzwiecki, H. J. Lenz, F. Innocenti, M. R. Mahoney, B. O’Neil, J. Shaw, et al. “CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon.” Annals of Oncology 25 (June 1, 2014): ii112. https://doi.org/10.1093/annonc/mdu193.19.
Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O’Neil B, et al. CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon. Annals of Oncology. 2014 Jun 1;25:ii112.
Venook, A., et al. “CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon.” Annals of Oncology, vol. 25, June 2014, p. ii112. Scopus, doi:10.1093/annonc/mdu193.19.
Venook A, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O’Neil B, Shaw J, Polite B, Hochster H, Atkins J, Goldberg R, Mayer R, Schilsky R, Bertagnolli M, Blanke C. CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (MFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the Colon. Annals of Oncology. 2014 Jun 1;25:ii112.
Published In
Annals of Oncology
DOI
EISSN
1569-8041
ISSN
0923-7534
Publication Date
June 1, 2014
Volume
25
Start / End Page
ii112
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences